Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
InhaleRx Limited ( (AU:IRX) ) just unveiled an update.
InhaleRx Limited has received approval from the Bellberry Human Research Ethics Committee to commence a Phase 1 clinical trial for its investigational therapy, IRX-616a, aimed at treating panic disorder. The trial, which will be conducted at the CMAX facility in Adelaide, will assess the safety and pharmacokinetics of a synthetic CBD aerosol delivered via inhaler to provide rapid relief for panic attacks. This development marks a significant milestone for InhaleRx as it advances its clinical program with full funding from Clendon Biotech Capital, potentially offering a new treatment option for a condition with limited current therapies.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company focused on creating rapid-onset inhaled therapies for unmet medical needs in pain management and mental health sectors. The company aims to secure U.S. FDA approval for its products using efficient regulatory pathways and has a funding partner providing up to $38.5 million to accelerate its development programs.
Average Trading Volume: 262,266
Technical Sentiment Signal: Hold
Current Market Cap: A$7.47M
For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.